Navigation Links
Chemo Combo Shows Promise Against Ovarian Cancer
Date:4/19/2009

Lab-based study focused on certain types of malignancies

SUNDAY, April 19 (HealthDay News) -- Adding the drug dasatinib to a standard, two-drug chemotherapy regimen for treating ovarian cancer boosted the effectiveness of the drugs in laboratory tests, new research shows.

Researchers at the Duke Comprehensive Cancer Center added dasatinib, along with carboplatin and paclitaxel, to four types of ovarian cancer cells.

In some types of ovarian cancers, a pathway called SRC is involved in the abnormal cell proliferation, said Dr. Deanna Teoh, a fellow in gynecologic oncology at Duke and lead investigator on this study.

"By examining gene expression data, we determined that the combination of the leukemia drug dasatinib (Sprycel) made carboplatin and paclitaxel more effective in cell lines with higher levels of SRC expression and SRC pathway deregulation," Teoh said.

Dasatinib, which is marketed by Bristol-Meyers Squibb under the brand name Sprycel, is FDA-approved for treating leukemia.

"These findings indicate that we may be able to direct the use of a targeted therapy like dasatinib based on gene expression pathways in select ovarian cancers," she said.

The results of the study were to be presented Sunday at the American Association for Cancer Research annual meeting, in Denver.

Researchers examined four ovarian cancer cell lines, known as IGROV1, SKOV3, OVCAR3 and A2780. Three of the cell lines demonstrated high activation of SRC, and one demonstrated lower SRC expression. All were treated in lab dishes with various combinations of the chemotherapy drugs dasatinib, carboplatin and paclitaxel.

"We found that the addition of dasatinib to standard therapy in the three cell lines with significant SRC pathway deregulation -- IGROV1, OVCAR3 and A2780 -- enhanced the response of the cancer cells to therapy," Teoh said. "Conversely, in SKOV3, which has minimal SRC protein expression and pathway deregulation, we saw the least amount of anti-cancer activity when we added dasatinib."

The results of the study support further investigation of targeted biologic therapy using a SRC inhibitor in some ovarian cancers, Teoh said. Currently a phase 1 trial of a combination of dasatinib, paclitaxel and carboplatin is available for women with advanced or recurrent ovarian, tubal and peritoneal cancers, the researchers said.

More information

The American Cancer Society has more on ovarian cancer.



-- Jennifer Thomas



SOURCE: Duke Comprehensive Cancer Center news release, April 19, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Chemotherapy may be culprit for fatigue in breast cancer survivors
2. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
3. To evade chemotherapy, some cancer cells mimic stem cells
4. New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas
5. PET scans can accurately detect a breast tumors response to chemotherapy
6. Chemotherapy with gemcitabine delays progression of operable pancreatic cancer
7. New Software Program Helps Breast Cancer Survivors and Patients Fight Chemofog
8. Medicare modernization act did not change chemotherapy as feared
9. HER-2 status predicts success of chemotherapy in breast cancer treatment, study finds
10. Cancer conflict with chemotherapy treatment
11. Intra-arterial combination chemotherapy induces long-term survival for hepatocellular carcinoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... The Dan Carlisle Agency, an ... County, is announcing the launch of a charity drive to raise support and ... women and children in Birmingham has grown steadily since the 1980’s, and the ...
(Date:12/8/2016)... Louis, MS (PRWEB) , ... December 08, 2016 , ... ... that serve commercial and residential clients in and around the Hancock County area, is ... for the Hancock County Food Pantry. , The Hancock County Food Pantry has worked ...
(Date:12/7/2016)... ... December 07, 2016 , ... DrugDev again demonstrated its dedication to ... of the early adopters completing EU-U.S. Privacy Shield Certification from the U.S. Department of ... both sides of the Atlantic with a mechanism to comply with EU data protection ...
(Date:12/7/2016)... ... December 07, 2016 , ... Kenall Manufacturing, a leader in sealed healthcare lighting ... MPCNGX is a multi-function, sealed, LED luminaire that meets the needs of everyone in ... it’s needed. , A 2’ x 4’ model features four modes: reading, ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... Smart Device Remote Control through a new partnership with Splashtop Inc. This remote ... its mobile solutions to help businesses maximize their uptime and productivity. , Wavelink ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016  Diplomat Pharmacy, Inc. (NYSE: DPLO) has ... 2016 Top Workplaces National Standard. To learn ... ... (PRNewsFoto/Diplomat Pharmacy, Inc.) ... an employee survey administered by WorkplaceDynamics, LLC, a research firm specializing ...
(Date:12/8/2016)... 8 de dezembro de 2016  A Mederi Therapeutics Inc . anunciou ... tratamento não cirúrgico para a doença do refluxo gastroesofágico (DRGE). Foto ... ... Live Stretta procedure performed and broadcast during the ... Wuhan Union Hospital ...
(Date:12/8/2016)... DANVILLE, Pa. , Dec. 8, 2016  A ... physicians reports that the use of opioid therapy to ... actually increase the likelihood of more harmful consequences, including ... Davis , M.D., and Zankhana Mehta , M.D., ... current research on chronic opioid therapy. The study was ...
Breaking Medicine Technology: